Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation with a Buy rating and a price target of $190. Ryan views Insulet as the dominant player in the tubeless insulin pump market with one of the strongest growth profiles in medical devices, and believes the stock has already discounted concerns about rising competition and pharmacy channel pressure. The analyst also considers fears over GLP-1 weight-loss drugs shrinking the insulin delivery market to be exaggerated and already reflected in the valuation.
Insulet CorporationDeutsche Bank initiated coverage with a Buy rating and $190 price target, a positive analyst valuation call.